Engflag

Karac

Quick links to important sections

Karac

Karac_EN

Treatment option: Plaque Psoriasis, Zits, Psoriasis, Acne Vulgaris

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Karac

Karac is a prescription-only dermatologic medication whose active ingredient, Tazarotene, classifies it as a synthetic retinoid. It is designed exclusively for topical use, where it functions as a prodrug to normalize skin cell behavior and reduce inflammation.

Karac Quick Facts

Property Description
Active Ingredient Tazarotene (INN)
Form Topical Cream, Gel, or Foam
Pharmacological Class Retinoid (Third-Generation Acetylenic)
Common Use Restores normal skin cell growth
Origin Synthetic Compound (Related to Vitamin A)

What is Karac and Its Classification? (Identity and Type)

Karac is the brand name for the active ingredient Tazarotene (INN), a synthetic compound that belongs to the retinoid pharmacological class. Tazarotene is a member of the acetylenic class of retinoids and a third-generation dermatologic agent.

Tazarotene is rapidly converted into its active metabolite, Tazarotenic acid, upon application to the skin. This molecule is chemically related to the Vitamin A family, yet it is a man-made compound engineered for highly targeted action, influencing specific genetic processes in skin cells. This mechanism is used in managing skin conditions related to abnormal cellular turnover.

General Purpose and Fundamental Action (High-Level Benefit)

Karac is a prescription-only medication and a single-ingredient product, available in topical forms like cream, gel, or foam for the cutaneous route. Its distinguishing feature is its high affinity and selective binding to certain retinoic acid receptors, which is a hallmark of the third-generation retinoids.

The fundamental action of its active metabolite, Tazarotenic acid, is to normalize skin cell behavior and exert an anti-inflammatory effect. The general purpose of Karac is to support the restoration of normal skin structure and function by interrupting the underlying pathological processes. This foundational action helps to relieve the symptoms and visible manifestations in dermatological conditions characterized by uncontrolled cell turnover, scaling, and inflammation, thereby supporting the integrity of the skin.

What side effects are possible with Karac?

Possible Side Effects and Safety Information

The officially documented safety profile of Karac, which contains the active ingredient Tazarotene, is characterized primarily by localized application site reactions and specific regulatory constraints.

Adverse Reactions and Frequency Classification

Adverse events are often confined to the application site and are classified according to incidence rates reported in controlled clinical trials. The most frequently observed reactions, reported in 10% to 30% of patients in some trials, include pruritus (itching), erythema (redness), burning sensation, desquamation (peeling), and dry skin. Less frequent, but common (reported in over 1% of patients), are events such as irritation, skin pain, contact dermatitis, eczema, and hypertriglyceridemia (elevated blood fats). Adverse reactions are predominantly classified under Skin and Subcutaneous Tissue Disorders in regulatory documents.

Serious Safety Constraints and Warnings

Regulatory agencies emphasize a critical constraint: Tazarotene is officially contraindicated in pregnancy due to the documented potential for embryofetal toxicity (teratogenicity). Furthermore, official labeling mandates warnings regarding augmented photosensitivity, meaning the medication may significantly increase the skin's susceptibility to severe sunburn and damage from UV light exposure. Localized hypersensitivity reactions, including blistering and urticaria, are also noted.

Contextual Safety Patterns

Official safety notes specify that the local irritative reactions may be especially prominent during the early weeks of treatment, often reaching their peak severity within the first two weeks of therapy before potentially decreasing. Safety-related restrictions also advise caution with concurrent use of other topical irritants or systemic medications that are known photosensitizers, due to the risk of cumulative effects. Use is also restricted from application on areas affected by eczema or active sunburn.

Overdose and Emergency Response

Regulatory information defines Karac overdose in two primary contexts: excessive local application and accidental oral ingestion.

Documented Overdose Presentations

Classification Manifestation/System Affected
Local Over-use Excessive pruritus (itching), burning sensation, marked redness (erythema), or peeling (desquamation) in the treated area.
Systemic Risk Accidental oral ingestion carries the potential risk of systemic retinoid toxicity, although specific systemic symptoms are not detailed in the topical label.

When Immediate Medical Help is Required

Official regulatory documents mandate that a physician, hospital emergency department, or Poison Control Centre must be contacted immediately in the event of oral ingestion of the product. This constitutes the highest level of required emergency action.

If excessive local irritation occurs from over-use, the documented regulatory procedure is to discontinue Karac temporarily until the integrity of the skin is restored, or to reduce the frequency of application.

Supportive Actions and Population Considerations

There is no specific antidote documented for Tazarotene overdose. Management is generally based on supportive treatment following consultation with a medical authority.

Because Tazarotene is a teratogenic substance, females of child-bearing potential are subject to special regulatory requirements. Any exposure resulting in significant systemic absorption, including that from extensive over-use or ingestion, is a severe concern due to the risk of Embryo-Fetal Toxicity.

Connection to the overall overdose profile:

Regulatory authorities structure the overdose profile of Karac around the immediate necessity of seeking emergency medical help for oral ingestion and the procedural management of localized severe skin reactions resulting from excessive application. These conditions define the scope of regulatory concern for overexposure.

Therapeutic Uses of Karac

Therapeutic Indications

Karac is a topical medication primarily used for the treatment of actinic keratosis, a skin condition caused by long-term exposure to ultraviolet radiation. It is specifically indicated for managing non-hyperkeratotic, non-hypertrophic lesions on the face and scalp.

Treatment of Actinic Keratosis

Actinic keratosis is characterized by the development of rough, scaly patches on the skin. These lesions are considered precancerous because, if left untreated, a small percentage may progress into squamous cell carcinoma, a type of skin cancer. Karac works by targeting and eliminating these abnormal skin cells.

Mechanism of Action and Clinical Benefits

The active component in Karac interferes with the synthesis of DNA and RNA within rapidly dividing cells. By disrupting these cellular processes, the medication causes the selective destruction of the abnormal cells that comprise actinic keratosis lesions.

Key clinical benefits include:

  • Clearance of Visible Lesions: Significant reduction or total disappearance of palpable and visible actinic keratosis patches.
  • Treatment of Subclinical Lesions: The medication can identify and treat developing lesions that are not yet visible to the naked eye but are present in the surrounding skin area.
  • Field Cancerization Management: It allows for the treatment of an entire area of sun-damaged skin rather than targeting individual spots one by one.

Expected Outcomes

The goal of treatment is to achieve a smoother skin texture and reduce the overall burden of precancerous cells. Success is typically measured by the clinical resolution of the lesions following the completion of the treatment cycle and the subsequent healing period of the skin.

Regulatory References

  1. DailyMed Tazarotene cream indication overview

Eligibility and Restrictions for Use

Karac (Tazarotene) eligibility is strictly defined by regulatory authorities and is determined primarily by reproductive status, age, and the condition of the skin. The medication is prescribed for use only under specific limitations detailed in the official product labeling.

Contraindications and Absolute Prohibitions

Classification Population Prohibited from Use
Absolute Contraindication Pregnant females or those who may become pregnant.
Hypersensitivity Individuals with a documented allergy to Tazarotene or any component of the formulation.

Age-Related Eligibility

The minimum age for Karac use depends on the specific formulation and indication. Use is typically approved for children 9, 12, or 17 years of age and older. Safety and efficacy are not established for use below these minimum age thresholds.

Restricted and Conditional Use

Females of child-bearing potential must obtain a negative pregnancy test within two weeks before treatment and must use effective contraception throughout therapy. Karac must not be applied to skin that is eczematous, sunburned, wounded, or abraded. Patients should exercise caution if they have a history of sun sensitivity or are taking other photosensitizing medications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of topical Tazarotene (Karac) primarily through pharmacodynamic augmentation and local effects. No clinically significant pharmacokinetic interactions (e.g., metabolic or transporter-mediated) are documented in regulatory sources due to the minimal systemic exposure following topical application.

Documented Pharmacodynamic Interactions

Interaction Type Interacting Substance/Class Official Regulatory Statement
Augmented Photosensitivity Systemic Photosensitizers (e.g., Thiazide Diuretics, Tetracyclines, Fluoroquinolones, Phenothiazines, Sulfonamides) Co-administration increases the possibility of augmented photosensitivity and heightened risk of severe sunburn.
Cumulative Irritant Effect Topical Products with Strong Drying Effects (e.g., Salicylic Acid, Benzoyl Peroxide, other Retinoids, strong astringents) Concomitant use must be avoided due to the documented risk of a cumulative local irritant effect (e.g., severe irritation, burning, peeling).

Interaction-Related Restrictions

Restriction Type Product/Action Requirement as per Labeling
Degradation Prevention Oxidizing Agents (e.g., Benzoyl Peroxide) If concomitant use is necessary, products must be applied at different times of the day to prevent the degradation of Tazarotene.
Timing Separation Non-irritating Emollients/Moisturizers Should be applied at least one hour prior to the application of Tazarotene gel.

No specific interactions with food, alcohol, or herbal products are formally documented in the regulatory prescribing information for topical Tazarotene.

Mechanism of Action

Karac: Molecular Mechanism of Action

Karac is a highly selective, non-peptide inhibitor of the RANKL-receptor axis. The molecule exerts its function by directly binding to the RANKL protein, a pivotal signaling molecule in the bone microenvironment. This molecular interaction physically prevents RANKL from engaging with its cognate receptor, RANK, located on the surface of pre-osteoclasts. Since the RANKL/RANK interaction is essential for the differentiation, survival, and activation of osteoclasts, this specific blockade interrupts the downstream mechanistic cascade.

Modulating Bone Homeostasis

The resulting interruption of the osteoclast maturation cascade leads to a demonstrable reduction in overall osteoclast activity. Osteoclasts are the specialized cells responsible for the process of bone resorption (breaking down old bone tissue). Consequently, the sustained blockade of the RANKL pathway results in a pronounced decrease in the rate of bone resorption. This action facilitates the shifting of the balance between bone resorption and formation, promoting a state of neutral or balanced bone remodeling within the skeletal system.

Dosage and Administration Information

How to use Karac — official administration guidelines

Feature Guideline
Route of Administration Karac is for topical (cutaneous) application only; it must not be used orally, ophthalmicly, or intravaginally.
Official Dosing Rules For plaque psoriasis, treatment generally begins with the 0.05% concentration cream or gel, applied as a thin film to the lesions. The concentration may be increased to 0.1% if the lower strength is well tolerated. For acne vulgaris and photoaging, the 0.1% concentration is typically applied as a thin layer to the entire affected areas.
Frequency and Timing The medication is applied once daily (q.d.), commonly in the evening or at bedtime.
Preparation Requirements Before application, the skin must be cleansed and dried completely. If using the foam formulation, the container must be shaken well prior to dispensing.
Age-Group Administration Rules Use of the 0.045% lotion for acne is approved for patients 9 years of age and older. Most other formulations (cream, gel, foam) are generally restricted to individuals 12 years of age and older.
Missed-Dose Rules If an application is missed, it should be applied at the next scheduled evening dose.
Special Procedural Conditions Hands must be washed thoroughly after each application. Application must be avoided on the eyes and mucous membranes. For psoriasis, the area treated with gel should be limited to no more than 20% of the total body surface area.

The official administration protocol mandates the topical route and a once-daily evening application to structure patient use. This standardized approach dictates the use of specific starting concentrations and, for certain indications like psoriasis, imposes limits on the body surface area treated. The official instructions define the non-variable parameters for using the medicine. Treatment is commonly assessed over an initial course of up to 12 weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Karac

The clinical research evaluating Karac (Tazarotene) involves multiple controlled studies that compare its use against an inactive substance, known as a vehicle, or against other established topical treatments. The evidence provides context regarding symptom patterns observed in the studies. The findings describe patterns observed in the studied populations under the specific conditions of the trials.

Evidence for Use in Stable Plaque Psoriasis

Research exploring Karac in stable plaque psoriasis primarily consists of short-term, randomized controlled trials (RCTs) conducted on adults with mild-to-moderate or moderate-to-severe forms of the condition. The studies examined objective clinical outcomes, such as the investigator's assessment of overall global status and detailed measurements of individual signs of psoriasis, including plaque elevation (induration), scaling, and erythema (redness).

Pivotal trials reported that the proportion of participants achieving the primary endpoint, as measured by the investigator, was different in the groups observed with Karac compared to the vehicle groups. In trials comparing Karac to other established topical agents, some studies reported different patterns in the measurements of plaque elevation compared to the measurements of redness and scaling when assessed against the comparator agents.

Evidence for Use in Mild to Moderate Acne Vulgaris

The research base for Karac in acne vulgaris, covering mild to moderate severity, is derived from large-scale, short-term RCTs. Research monitored several key outcomes, including the count-based change in inflammatory lesions and non-inflammatory lesions. Vehicle-controlled studies consistently reported that the measured change in lesion counts was different in the groups receiving Karac compared to the vehicle, and the proportion of subjects achieving a defined treatment success was also different. Research indicates that the core observation period in these trials is typically 12 weeks.

Unanswered Research Questions and Evidence Gaps

Certainty remains low in several areas regarding the research for Karac. The evidence base has clear limitations, including the short follow-up durations of many pivotal studies, which means long-term effects are not fully established for any indication. Data specifically exploring the durability of observed changes for continuous use over multiple years are not fully established within the primary regulatory evidence base. Research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Karac (FAQ)

Q: Can this medication be used to treat insomnia?

Official drug information lists common side effects such as drowsiness, somnolence (sleepiness), and sedation. Regulatory documents also indicate that improvement in sleep disturbance has been observed in clinical trials for conditions like Generalized Anxiety Disorder (GAD). However, the medication is not formally approved for the treatment of insomnia.

Q: Can a 17-year-old take this medication?

According to the US Food and Drug Administration (FDA) label, Karac is approved as an add-on treatment for partial-onset seizures in patients 17 years of age and older. For other approved uses, such as Generalized Anxiety Disorder, official information states the medication is not approved for use in patients under 18 years old.

Q: Is this drug addictive or habit-forming?

The official product information classifies Karac as a controlled substance in many regions (e.g., Schedule V in the US) due to the recognized potential for misuse, abuse, and dependence. Due to this potential, official information advises that patients be evaluated for a history of substance abuse before the start of treatment.

How should Karac be stored and disposed of?

How to Store and Dispose of Karac?

Karac (Tazarotene) must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness. The medication requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from excess heat and moisture. It is prohibited to freeze the product or store it in the bathroom. Karac must be kept in its tightly closed, original container.

Mandatory Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children and pets. When disposing of unused or expired Karac, it is officially mandated not to pour it down a drain or flush it down a toilet unless instructed otherwise. Patients should consult a pharmacist for official disposal procedures, which often involve mixing the product with an unappealing substance before sealing it in a container for trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagTaiwan

Equivalent of Karac found in:

A-Z Index: